Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Cash & Equivalents (2016 - 2025)

Mesa Laboratories (MLAB) has disclosed Cash & Equivalents for 16 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 6.05% to $29.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.0 million through Dec 2025, up 6.05% year-over-year, with the annual reading at $27.3 million for FY2025, 3.17% down from the prior year.
  • Cash & Equivalents hit $29.0 million in Q4 2025 for Mesa Laboratories, up from $20.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $278.3 million in Q3 2021 to a low of $20.4 million in Q3 2025.
  • Historically, Cash & Equivalents has averaged $67.8 million across 5 years, with a median of $30.7 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 224.24% in 2021 and later crashed 88.37% in 2022.
  • Year by year, Cash & Equivalents stood at $51.7 million in 2021, then plummeted by 49.52% to $26.1 million in 2022, then increased by 8.13% to $28.2 million in 2023, then dropped by 3.2% to $27.3 million in 2024, then increased by 6.05% to $29.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for MLAB at $29.0 million in Q4 2025, $20.4 million in Q3 2025, and $21.3 million in Q2 2025.